Brokerages Set Charles River Laboratories International, Inc. (NYSE:CRL) Price Target at $200.79

Charles River Laboratories International, Inc. (NYSE:CRL) has been assigned a consensus rating of “Reduce” from the seventeen brokerages that are currently covering the stock, Marketbeat reports. Three analysts have rated the stock with a sell rating, thirteen have given a hold rating and one has given a buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $200.79.

A number of equities research analysts recently commented on CRL shares. William Blair downgraded Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 22nd. CLSA downgraded shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price target on the stock. in a research report on Monday, November 18th. Morgan Stanley decreased their price objective on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating for the company in a report on Wednesday, February 5th. UBS Group reiterated a “neutral” rating and issued a $185.00 target price (down from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. Finally, The Goldman Sachs Group lowered their price objective on shares of Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating for the company in a research report on Thursday, January 23rd.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Wellington Management Group LLP lifted its stake in Charles River Laboratories International by 135,927.9% in the 3rd quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company’s stock valued at $736,819,000 after purchasing an additional 3,738,018 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its position in shares of Charles River Laboratories International by 40.7% in the third quarter. Allspring Global Investments Holdings LLC now owns 1,760,781 shares of the medical research company’s stock valued at $346,821,000 after buying an additional 509,163 shares during the last quarter. Raymond James Financial Inc. acquired a new position in shares of Charles River Laboratories International during the 4th quarter worth approximately $42,776,000. Cooke & Bieler LP raised its stake in Charles River Laboratories International by 42.1% in the 4th quarter. Cooke & Bieler LP now owns 426,767 shares of the medical research company’s stock valued at $78,781,000 after acquiring an additional 126,372 shares during the period. Finally, Mizuho Securities USA LLC lifted its holdings in Charles River Laboratories International by 2,336.4% during the 3rd quarter. Mizuho Securities USA LLC now owns 96,871 shares of the medical research company’s stock valued at $19,081,000 after purchasing an additional 92,895 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Charles River Laboratories International Stock Performance

Shares of Charles River Laboratories International stock opened at $154.93 on Friday. The firm has a fifty day moving average of $178.90 and a two-hundred day moving average of $192.24. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48. The stock has a market capitalization of $7.92 billion, a price-to-earnings ratio of 19.39, a PEG ratio of 6.47 and a beta of 1.37. Charles River Laboratories International has a 52 week low of $154.01 and a 52 week high of $275.00.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).